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K, Tavtigian S, Liu Q, et al (1994) A strong candidate forIt is interesting to note that in a recent report, Dunning
the breast and ovarian cancer susceptibility gene BRCA1.et al. (1997) examined whether common BRCA1 vari-
Science 266:66–71ants could confer modest individual risk as opposed to
Monteiro ANA, August A, Hanafusa H (1996) Evidence forthe highly penetrant mutations found in multiple case
a transcriptional activation function of BRCA1 C-terminalfamilies of early onset of breast and ovarian cancer.
region. Proc Natl Acad Sci USA 93:13595–13599
Examining four polymorphisms, one of which is in the Neuhausen SL, Marshall CJ (1994) Loss of heterozygosity in
C-terminal region (Ser1613Gly, the same mutation used familial tumors from three BRCA1-linked kindreds. Cancer
here), Dunning et al. concluded that haplotypes con- Res 54:6069–6072
taining these variants do not contribute signiﬁcantly to Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J,
disease predisposition. Our data agree with this analysis, Ashley T, et al (1997) Association of BRCA1 with Rad51
in mitotic and meiotic cells. Cell 88:265–2758since the construct containing this variant had wild-type
Smith SA, Easton DF, Evans DGR, Ponder BAJ (1992) Alleleactivity in our assay.
losses in the region 17q12-21 in familial breast and ovarianIn conclusion, we show here that two common vari-
cancer involve the wild-type chromosome. Nat Genet 2:ants of BRCA1 that do not contribute to disease predis-
128–131position show wild-type transcriptional activity. More-
over, our results strongly suggest that the Ser1613Cys
Address for correspondence and reprints: Dr. Hidesaburo Hanafusa, Labora-mutation may predispose the carrier to disease. We be- tory of Molecular Oncology, Rockefeller University, 1230 York Avenue, New
lieve these results provide additional indication that York, NY 10021.
*Present afﬁliation: Department of Immunology, R. W. Johnson Pharmaceuti-BRCA1 acts as a tumor suppressor in a transcription-
cal Research Institute, Raritan, NJ.dependent manner. Furthermore, these data validate the  1997 by The American Society of Human Genetics. All rights reserved.
use of the yeast transcription assay to predict disease 0002-9297/97/6103-0033$02.00
predisposition conferred by mutations found in the C-
terminal region.
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studied in the United States and in northern Europe. In
agreement with the data from this southern European
References population, we have recently found that among nearly
400 Ashkenazi Jews the gene frequency of the C292YBreast Cancer Information Core (1997) http://www.nhgri.nih
mutation in HLA-H was only 0.013, compared with.gov/Intramural research/Lab transfer/Bic/
Chapman MS, Verma IM (1996) Transcriptional activation 0.07 in the non-Jewish American white population
by BRCA1. Nature 382:678–679 (Beutler and Gelbart 1997). These ﬁndings and those of
Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Carella et al. seem quite consistent with the putative
Oakes S, Wilson C, et al (1997) Common BRCA1 variants Celtic origin of this mutation (Jazwinska et al. 1995).
and susceptibility to breast and ovarian cancer in the general We sequenced the entire HLA-H coding region of 16
population. Hum Mol Genet 6:285–289 chromosomes in patients with hemochromatosis who
Easton DF, Bishop DT, Ford D, Crockford GP, Breast Cancer
did not have the C282Y mutation and, like Carella etLinkage Consortium (1993) Genetic linkage analysis in fa-
al., found no additional mutations. The surprising lackmilial breast and ovarian cancer: results from 214 families.
of other mutations suggests the possibility that theAm J Hum Genet 52:678–701
C282Y mutation causes a gain in function (Beutler etKoonin EV, Altschul SF, Bork P (1996) Functional motifs. Nat
al. 1997a). On the other hand, the accumulation of ironGenet 13:266–268
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman in mice with targeted disruption of b2 microglobulin
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(Rothenberg and Voland 1996; Santos et al. 1996) im- mutation. The presence or absence of the H63D muta-
tion trans to the C282Y mutation in heterozygotes inplies that failure to display the molecule on the cell sur-
face might be sufﬁcient to cause iron-storage disease. hemochromatosis patients is shown in table 1. A two-
tailed Fischer’s exact test gives a remarkable P-valueIn the original article by Feder et al. (1996) and in
õ10010. It is difﬁcult, in view of such data, to see anyour conﬁrmation of these studies (Beutler et al. 1996),
cause for controversy regarding the relationship betweenit was clearly shown that there was a highly signiﬁcant
this mutation and hemochromatosis. While tight linkagerelationship between the other mutation that is com-
with another mutation cannot be ruled out, Feder et al.monly found on HLA-H, namely 187G (H63D) and
(1996) found no other candidate genes in a 250-kb re-hemochromatosis. But there now seems to be consider-
gion surrounding the gene, and a cause-and-effect rela-able confusion regarding the role of this mutation. Ja-
tionship is by far the more parsimonious explanation.zwinska et al. (1996) and Jouanolle et al. (1996) both
The fact that the H63D mutation does not occur onimplied that this mutation does not play a causal role
the ancestral chromosome is to be expected, since itin hereditary hemochromatosis, and Carella et al. (1997)
represents an independent mutational event and shouldrefer to its role as being controversial. I suggest that
be, and is, associated with its own haplotype.there is no reason for controversy; the population data
2. Homozygotes for this mutation are rare amongfrom all studies published thus far show convincingly a
patients. This is true, but neither we nor anyone elsestrong relationship.
had suggested that the homozygous state for the H63DWhile Carella et al. (1997) do not reject the possibility
would cause hemochromatosis. There is no reason forthat a relationship exists between H63D and hemochro-
assuming that it would merely because the compoundmatosis, they suggest that ‘‘several lines of evidence indi-
heterozygous C282Y/H63D state causes hemochroma-cate that this variant is a polymorphic change’’ (p. 831).
tosis. However, very recent evidence suggests that H63D
1. It attains a similar frequency in patients and con- homozygotes may be more prevalent in the hemochro-
trols (and occurs on chromosomes unrelated to the an- matosis population than in the control population
cestral one). This, indeed, is the argument that has been (Beutler et al. 1997b).
put forward by others. For example, Jouanolle et al. 3. Compound heterozygotes have been found in the
(1996) also conclude that the H63D mutation does not normal population. Both Feder et al. (1996) and our
bear a relationship to hemochromatosis, reasoning that group (Beutler 1997; Beutler et al. 1996) have pointed
the frequency of the mutation, 0.16, is the same in the out that the penetrance of the compound heterozygous
hemochromatosis and control group. Similarly, Carella state must be low, because the Hardy-Weinberg equilib-
et al. (1997) point out that in their study the mutation rium predicts many more compound heterozygotes in
frequency among hemochromatosis patients is 10/150 the population than C282Y homozygotes. Feder et al.
(0.067) while it is 10/100 (0.10) in the control popula- (1996) estimated a penetrance of 0.5%, our data suggest
tion. However, one must take into account the fact that penetrance of 1.5% (Beutler et al. 1996), and those of
no chromosome that bears the C282Y mutation has ever Jouanolle et al. (1996) of 0.44%. In their normal popu-
been found to contain the H63D mutation. Of the 150 lation, the gene frequency of H63D is 0.165 and that of
chromosomes that Carella et al. (1997) analyzed, only C282Y is 0.0288. According to the Hardy-Weinberg
47 are ‘‘at risk’’ for carrying the H63D mutation, and equilibrium, the predicted H63D/C282Y compound het-
10 of these chromosomes contain this mutation, a fre- erozygote frequency is 0.165 1 0.288 1 2 Å 0.0095;
quency of 0.21, compared to the 0.10 control frequency. that of C282Y/C282Y is 0.02882 Å 0.000829. The ex-
The strong evidence that proves the relationship of
the H63D mutation to the disease is the frequency of
the H63D mutation in patients with hemochromatosis
Table 1who carry only one copy of C282Y. If the H63D muta-
tion were unrelated to hemochromatosis, one would Relationship between the Presence or Absence of the 187G
(H63D) Mutation and Hemochromatosis in Heterozygotes for thealso expect the incidence of this mutation to be the same
845A (C282Y) Mutationin such patients as in the general population, but this is
not the case. In the series of Feder et al. (1996), 8/9
845A/187C 845A/187G Total
patients heterozygous for the C282Y mutation carried
the H63D mutation, whereas in our series it was 8/10 Hemochromatosis 10 28 38
Normal 56 6 62(Beutler et al. 1996); Jouanolle et al. (1996) found 3/3,
Total 66 34 100Borot et al. (1997) 4/8, and Carella et al. now report 5/
8. Thus, 28/38, or an impressive 73.7%, of the chromo- NOTE.—These data are a compilation of all published data (Beutler
somes at risk in hemochromatosis patients heterozygous et al. 1996; Jouanolle et al. 1996; Borot et al. 1997; Carella et al.
1997; Roberts et al. 1997). Fisher’s exact test gives P õ 10010.for C282Ywho have been analyzed contained the H63D
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population. Paper presented at the scientiﬁc symposium Ad-pected ratio at 100% penetrance is 11.45 in favor of
vances in Jewish Genetic Diseases,Mt. SinaiMedical Center,the compound heterozygote, but the observed ratio is
New York, October 12–143/59 (0.05). Thus, only 0.05/11.45, or 0.44%, of the
Beutler E (1997) Genetic irony beyond haemochromatosis:expected compound heterozygotes appear in the patient
clinical effects of HLA-H mutations. Lancet 349:296–297population. The low penetrance of this genotype is sup-
Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstoneported by the fact that all of the compound heterozy-
R, Pockros P, et al (1996) Mutation analysis in hereditary
gotes with disease we have encountered are males, a hemochromatosis. Blood Cells Mol Dis 22:187–194
known risk factor for the disease. Beutler E, Gelbart T (1997) HLA-H mutations in the Ashken-
azi Jewish population. Blood Cells Mol Dis 23:95–98The relationship between the two HLA-H mutations
Beutler E, West C, Gelbart T (1997a) HLA-H and associatedand hemochromatosis is analogous to that occurring in
proteins in patients with hemochromatosis. Mol Med 3:
several other diseases. One example is the interaction of 397–402
the hemoglobin S mutation with hemoglobin C or D. Beutler E, West C, Gelbart T, Felitti VJ (1997b) Genetic and
The compound heterozygotes, HbS/HbC or HbS/HbD, clinical description of hemochromatosis probands and het-
have a disease that is generally milder than the homozy- erozygotes: evidence that multiple genes linked to the major
gous S state, but neither homozygote (HbC/HbC or histocompatibility complex are responsible for hemochro-
matosis. Commentary. Blood Cells Mol Dis 23:145a–145bHbD/HbD) is affected with a sickling disorder. Simi-
Borot N, Roth MP, Malfroy L, Demangel C, Vinel JP, Pascallarly, the 1604T glucocerebrosidase Gaucher disease
JP, Coppin H (1997) Mutations in the MHC class I-likemutation is relatively common in the Jewish population
candidate gene for hemochromatosis in French patients. Im-(Allitto et al. 1996), but no 1604T homozygotes with
munogenetics 45:320–324Gaucher disease have ever been encountered. Com-
Carella M, D’Ambrosio L, Totaro A, Grifa A, Valentino MA,pound heterozygote with the severe 84GG mutation and
Piperno A, Girelli D, et al (1997) Mutation analysis of theeven the milder 1226G mutation, however, do manifest
HLA-H gene in Italian hemochromatosis patients. Am J
the disorder. Hum Genet 60:828–832
Thus, my conclusion from the considerable data that Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA,
have already been published in the brief time since the Basava A, Dormishian F, et al (1996) A novel MHC class
Feder et al. (1996) study appeared, including the recent I-like gene is mutated in patients with hereditary haemo-
article by Carella et al. (1997), is that the C282Y muta- chromatosis. Nat Genet 13:399–408
tion is the main, but not the only, HLA-H mutation Jazwinska EC, Cullen LM, Busﬁeld F, Pyper WR, Webb SI,
Powell LW, Morris CP, et al (1996) Haemochromatosis andinvolved in the cause of hereditary hemochromatosis.
HLA-H. Nat Genet 14:249–251The compound heterozygote of this mutation with the
Jazwinska EC, Pyper WR, Burt MJ, Francis JL, Goldwurm S,187G mutation is also at special risk for the develop-
Webb SI, Lee SC, et al (1995) Haplotype analysis in Austra-ment of hemochromatosis, but with a very low pene-
lian hemochromatosis patients: evidence for a predominanttrance. It is likely that most of the heterozygotes with
ancestral haplotype exclusively associated with hemochro-mild disease manifestations reported before the discov-
matosis. Am J Hum Genet 56:428–433ery of the HLA-H gene will prove, in fact, to be such
Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion
compound heterozygotes. ML, Yaouanq J, Mosser J, et al (1996) Haemochromatosis
and HLA-H. Nat Genet 14:251–252ERNEST BEUTLER
Roberts AG, Whatley SD, Morgan R, Worwood M, Elder GH,The Scripps Research Institute
Morgan RR (1997) Increased frequency of the haemochro-
Department of Molecular and Experimental Medicine matosis Cys282Tyr mutation in sporadic porphyria cutanea
La Jolla tarda. Lancet 349:321–323
Rothenberg BE, Voland JR (1996) b2 knockout mice develop
parenchymal iron overload: a putative role for class I genes
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